Therapy Areas: Oncology
Ferring expands gene therapy manufacturing capabilities
3 October 2024 -

Privately owned specialty biopharmaceutical group Ferring Pharmaceuticals announced on Thursday that it has opened a new manufacturing facility in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg).

The facility will help Ferring meet the growing demand for Adstiladrin, which is approved in the United States for the treatment of non-muscle invasive bladder cancer.

This investment is part of Ferring's commitment to ensuring the future supply of this therapy for patients.

Login
Username:

Password: